SCHEMBL24209668

SCHEMBL24209668

CC(C)(C)c1ccc(C(=O)CSc2nnnn2-c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.60
▸ TSHR P16473 3/20 0.59
▸ HPGD P15428 3/20 0.58
▸ ALPL P05186 4/20 0.57
▸ ALPG P10696 4/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ MEN1 O00255 7/20 0.55
▸ KMT2A Q03164 7/20 0.55
▸ ALDH1A1 P00352 7/20 0.54
▸ POLB P06746 5/20 0.54
▸ LMNA P02545 4/20 0.54
▸ KDM4E B2RXH2 3/20 0.54
▸ GAA P10253 3/20 0.54
▸ RECQL P46063 3/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ JAK2 O60674 2/20 0.54
▸ USP2 O75604 2/20 0.54
▸ THRB P10828 1/20 0.54
▸ APEX1 P27695 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21951986 0.91 MAPT (0.71) MAPTTSHRHPGDALPLALPG
SCHEMBL21952095 0.89 MAPT (0.64) MAPTTSHRHPGDALPLALPG
SCHEMBL21952058 0.87 MAPT (0.64) MAPTTSHRHPGDALPLALPG
SCHEMBL24209664 0.87 ALPL (0.73) MAPTTSHRHPGDALPLALPG
SCHEMBL24209682 0.87 MAPT (0.71) MAPTTSHRHPGDALPLALPG
SCHEMBL24209657 0.85 MAPT (0.82) MAPTTSHRHPGDALPLALPG
SCHEMBL21952033 0.85 MEN1 (0.73) MAPTTSHRHPGDALPLALPG
SCHEMBL24209661 0.85 MAPT (0.64) MAPTTSHRHPGDALPLALPG
SCHEMBL21952082 0.85 MAPT (0.64) MAPTTSHRHPGDALPLALPG
SCHEMBL21952054 0.85 MAPT (0.64) MAPTTSHRHPGDALPLALPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220016080-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS FUND PROFESOR NOVOA SANTOS (ES) 2022-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220016080-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS CHUK, HIPK3, HIPK1 MAPT 3296/4885TSHR 4382/4885HPGD 1570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback